Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when SLS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SLS SELLAS Life Sciences Group, Inc. 8-K

SELLAS Life Sciences reports 2025 full-year financial results

Filed March 19, 2026 · Period ending March 19, 2026 · ~1 min read

2 key changes 2 sections

Key Changes

  • medium

    SELLAS announced financial results for the year ended December 31, 2025, along with a corporate update via press release. Specific financial figures and operational details are contained in the attached exhibit.

  • medium

    The 8-K filing itself contains only the announcement of the press release; actual financial performance metrics and corporate developments require review of the full press release exhibit.

    Exhibit 99.1 view on EDGAR →

Summary

SELLAS Life Sciences filed an 8-K to announce its 2025 full-year financial results and provide a corporate update through a press release dated March 19, 2026. This is a routine earnings disclosure filing, with the substantive financial data and operational commentary contained in the attached press release exhibit rather than in the 8-K body itself. For retail investors, this represents a standard quarterly reporting event.

The actual financial performance, cash position, clinical trial progress, and management commentary on business developments will be found in the press release exhibit. Investors should review that document to assess the company's financial health and progress on its drug development programs. Watch for any guidance updates, clinical trial milestones, or cash runway discussions in the full press release to gauge near-term prospects.

Section-by-Section Diff

Event · Item 2.02 — Results of Operations and Financial Condition

~200 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added
Added 2025 financial results announcement medium

Added in current filing · verify on EDGAR →

On March 19, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.

SELLAS disclosed its full-year 2025 financial results through a press release. The 8-K itself does not contain the actual financial figures or corporate update details, which are in the attached press release exhibit. This is a standard earnings announcement filing.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

SELLAS filed an 8-K attaching a press release dated March 19, 2026; no material business event disclosed in the filing body.

1 Added
Added Press release attachment medium

Added in current filing · view on EDGAR →

99.1 Press Release dated March 19, 2026

The 8-K references an attached press release dated March 19, 2026, but the filing body itself contains no disclosure of the press release content or the underlying event. Without the exhibit text, the materiality and nature of the announcement cannot be determined from this filing.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify